Respiratory Syncytial Virus Vaccine (Abrysvo)
Respiratory Syncytial Virus Vaccine is an FDA-licensed reference biologic from Pfizer Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
Abrysvo Respiratory Syncytial Virus Vaccine
Pfizer Inc.
- Approved
- May 31, 2023
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Respiratory Syncytial Virus Vaccine, in chronological order.
Reference approval
Approval date of the reference Respiratory Syncytial Virus Vaccine product.
3 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for Respiratory Syncytial Virus Vaccine (Abrysvo)?
No 351(k) biosimilars or interchangeable biosimilars referencing Respiratory Syncytial Virus Vaccine are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.